Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Carmenta Bioscience to Develop Serum Diagnostic Test for Preeclampsia

Published: Thursday, January 31, 2013
Last Updated: Thursday, January 31, 2013
Bookmark and Share
Technology poised to transform ability of physicians to diagnose pregnant mothers.

Carmenta Bioscience, Inc. announced it has acquired the option for a worldwide, exclusive license from Stanford University to develop a set of tests enabling physicians to better diagnose and predict preeclampsia. Preeclampsia is a leading cause of preterm birth and maternal/fetal death, arising in 5-8% of pregnant mothers and characterized by high blood pressure and protein in the urine after week 20 of pregnancy.

The technology was discovered by Carmenta’s co-founders, Dr. Atul Butte and Dr. Bruce Ling of Stanford University. Their research uncovered a novel combination of clinically relevant, proprietary protein biomarkers in serum capable of identifying pregnant mothers with preeclampsia. An initial trial involving samples from 64 mothers verified the clinical accuracy of the biomarkers. The research was funded by the March of Dimes and the SPARK program at Stanford School of Medicine.

“Preeclampsia is difficult for physicians to accurately identify due to its complex pathophysiology. This multifaceted condition is best diagnosed using a modern, systems-biology based approach,” said Dr. Matthew Cooper, Carmenta’s President and Chief Executive Officer. “Building on the technology from Stanford, Carmenta is developing tests to meet the needs of the Maternal Fetal Medicine and OB-GYN community to diagnose preeclampsia in both symptomatic and asymptomatic mothers.”

“For years, MFMs and OB-GYNs have called for more objective, molecular diagnostic tests for preeclampsia. Carmenta is answering that call by developing tests capable of both confirming clinical diagnosis and predicting preeclampsia. Identifying pregnant mothers at highest risk for preeclampsia will allow physicians to better monitor and intervene, resulting in improved clinical outcomes and economic benefit to the healthcare system,” continued Dr. Cooper.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Uncovering Water Bear Resilience
A protein identified in water bears can protect DNA of human cells from lethal doses of radiation damage.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Stem Cells Growing 3D Lung-in-a-Dish
Researchers have created 3D lung-like tissue from lung-derived stem cells. The tissue can be used to study lung diseases.
The Genetics of Blood Pressure
Researchers have identifed areas of the genome associated with blood-pressure including 17 previously unknown loci.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!